BioWorld: The Daily Biopharmaceutical and Medical Technology …
网页Aviadobio, Astellas ink $2B+ frontotemporal dementia gene therapy deal. Aviadobio Ltd. has entered a potential $2.18 billion license and commercialization agreement for its frontotemporal dementia gene therapy, AVB-101, with Astellas Pharma... Daily news and analysis of the global biotechnology, pharmaceutical and medical technology industries.
BioWorld: The Daily Biopharmaceutical News Source
网页3 天之前 · Japan pledges to become ‘land of drug discovery’: Bio Japan 2024. The Japanese government is throwing full weight behind the Bioeconomy Strategy initiative to position Japan’s biopharmaceutical industry as both a key driver of economic growth and global drug discovery hub. SK Bioscience to invest $3M …
China - BioWorld
网页2024年10月3日 · Alphamab and JMT-Bio ink $439M antibody-drug conjugate China deal. Sep. 30, 2024. By Tamra Sami. No Comments. Jiangsu Alphamab Biopharmaceuticals Co. Ltd. is out-licensing its anti-HER2 bispecific antibody-drug conjugate, JSKN-003, to JMT-Bio Technology Co. for China rights in a deal worth up to …
Coronavirus - BioWorld
网页5 天之前 · In work at Shanghai Curegene Pharmaceutical Co. Ltd., synthesis and optimization of a series of SARS-CoV-2 3CL protease (3CLpro, Mpro) inhibitors led to the identification of compounds [I], [II] and [III] as lead candidates suitable for further evaluation, based on their enzymatic IC50s (14, 12 and 8.6 nM, respectively), cellular EC50s (36, 26 and 52 nM, respectively) and human liver microsome ...
Chemistry Nobel awarded for 3D protein design, prediction work
网页4 天之前 · David Baker, Demis Hassabis and John Jumper share the 2024 Nobel Prize in Chemistry for their contributions to the science of protein structure. David Baker was awarded half the prize “for computational protein design,” according to the Royal Swedish Academy of Sciences. Hassabis and Jumper shared the …
China biotechs rise to challenge Ozempic, Wegovy | BioWorld
网页2024年9月12日 · Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster therapies in China. At the heart of the GLP-1 boom is a nationwide obesity problem driven by a confluence of factors, including the rise of a modern, sedentary lifestyle, according to Clarivate. Despite ...
China - BioWorld
网页2024年10月1日 · Alphamab and JMT-Bio ink $439M antibody-drug conjugate China deal. Oct. 1, 2024. By Tamra Sami. No Comments. Jiangsu Alphamab Biopharmaceuticals Co. Ltd. is out-licensing its anti-HER2 bispecific antibody-drug conjugate, JSKN-003, to JMT-Bio Technology Co. for China rights in a deal worth up to …
New peptide antibiotics from the human microbiome | BioWorld
网页2024年8月22日 · The gastrointestinal tract could be key to developing new drugs to combat resistant bacteria. Computational analysis of the human microbiome has revealed a new class of peptides with antimicrobial potential that, once synthesized, inhibited the growth of several microorganisms in vitro and in vivo. “Antimicrobial resistance is one of the greatest threats to humanity, with more and more ...
Booster launches with $15M, new approach in proteasome activation
网页2 天之前 · Booster Therapeutics is ready to open up a new arm of the proteasome after raising $15 million in seed funding to advance small molecules it says can degrade multiple types of harmful proteins. Rather than tagging single disease proteins with a ubiquitin marker for degrading via 26S proteasomes, these compounds directly activate 20S proteasomes that naturally recognize disordered proteins ...
2024 a record year for biopharma deal activity despite September ...
网页2 天之前 · Biopharma deals in September amounted to $12.79 billion, marking a 20% drop in value from August’s $15.94 billion. Despite the month-to-month decline, the sector has seen strong momentum throughout the first three quarters of 2024, with total deal values reaching $149.02 billion. This represents a 14% increase from the $130.38 billion recorded during the same period in 2023, with 2024 ...